Clinical Trial Update: Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel + cetuximab with concurrent IMRT for locoregionally recurrent head and neck cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-04-23